
Jazz Pharmaceuticals Announces First Quarter 2025 Financial Results and Updates 2025 Financial Guidance
– Total revenues of $898 million in 1Q25 – – Xywav® and Epidiolex® revenues grew 9% and 10% year-over-year, respectively, in 1Q25 – – Completed submission of sNDA for Zepzelca® in 1L ES-SCLC – – Affirming 2025 revenue guidance; updating financial guidance …